To evaluate ALS pathology at this stage, we assessed astrocyte reactivity by evaluating the number of astrocytes staining for glial fibrillary acidic protein (GFAP) [48] and microglial activation by detecting the ionized calcium-binding adaptor molecule 1 (Iba1) marker [49]. This evidence concerns the gene GFAP and amyotrophic lateral sclerosis.